We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App




Endogenous Testosterone Levels Associated with Risk of Diabetes

By LabMedica International staff writers
Posted on 02 Jun 2020
Print article
Image: The QSight Triple Quad 400 Series Liquid Chromatography Mass Spectrometry (Photo courtesy of PerkinElmer).
Image: The QSight Triple Quad 400 Series Liquid Chromatography Mass Spectrometry (Photo courtesy of PerkinElmer).
High plasma levels of endogenous total and circulating free testosterone are associated with a two- to sevenfold increased risk for developing type 2 diabetes among young, healthy women without comorbidities.

The impact of endogenous androgens on risk of type 2 diabetes is well-established in women with established hyperandrogenism such as polycystic ovary syndrome (PCOS), a condition strongly associated with increased insulin resistance, but knowledge on plasma testosterone level per se as a risk factor, in women without established hyperandrogenism is lacking.

A team of Danish scientists led by those at Rigshospitalet (Copenhagen, Denmark) analyzed data from 8,876 healthy women (mean age, 38.5 years) who provided blood samples to measure plasma testosterone, dehydroepiandrosterone-sulfate (DHEAS), dihydrotestosterone (DHT) and sex hormone-binding globulin (SHBG) between January 2007 and December 2015 in a retrospective study. During 69,728 person-years, 69 women received a type 2 diabetes diagnosis.

Plasma testosterone was analyzed using liquid-chromatography tandem mass spectrometry (LC-MS). An in-house method was used from 2007 to 2010. In 2011 and onwards, the PerkinElmer CHS LC-MS Steroid kit (PerkinElmer, Waltham, MA; USA) was used for testosterone measurement. DHEA-S was initially analyzed using the Abbott Architect DHEA-S immunoassay (Abbott Diagnostics, Champaign, IL, USA), but was transferred to LC-MS when the PerkinElmer kit was implemented. DHT was initially measured by an in-house radioimmunoassay and plasma SHBG levels were assessed using the Abbott Architect SHBG immunoassay.

The investigators reported that that women in the highest quartiles for plasma total testosterone and calculated free testosterone were more likely to develop type 2 diabetes during follow-up versus women in the lowest quartile, with incidence rate ratios (IRRs) of 1.97 and 7.32, respectively. Levels of SHBG were inversely associated with type 2 diabetes, whereas DHEAS and DHT were not associated with incident type 2 diabetes. Results persisted after adjustment for age, plasma SHGB and socioeconomic factors.

Jon Jarløv Rasmussen, MD, PhD, an endocrinology specialist and first author of the study, said, “The findings of this study suggest high plasma levels of testosterone could play a role in the pathogenesis of type 2 diabetes among women. The incidence of type 2 diabetes was rather low in the study, but the results implicate that screening for type 2 diabetes among women with higher plasma levels of testosterone may be beneficial, even among women who are young and without established comorbidities, such as polycystic ovary syndrome.”

The authors concluded that higher levels of plasma total and free testosterone were associated with increased risk of type 2 diabetes among women. The study was published on May 5, 2020 in the Journal of the Endocrine Society.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.